Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:03:10.445Z.
Calculation as of: 2026-10-06T21:03:10.445Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80dc1f4e8b31b1f0ec5b4a1e5c631a71efe14c3ee5142d993ef0c896d26e8132
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$131.21M
EV/EBIT Ratio
N/A
TTM Avg
60.31x
3Y Avg
490.71x
5Y Avg
419.04x
Market Cap
$122.66M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | $127.98M | N/A | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | N/A | 60.31x | 490.71x | 419.04x |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | N/A | 3.95x | 3.95x | 3.95x |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $132.03M | N/A | 204.78x | 204.78x | 204.78x |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
